Immunohistochemical differences between mucinous and microglandular adenocarcinomas of the endometrium and benign endocervical epithelium

International Journal of Gynecological Pathology

Volumn 27, Issue 4, 2008, Pages 547-554

  Chekmareva, Marina ^a   Ellenson, Lora H ^b   Pirog, Edyta C ^b  

^a ROBERT WOOD JOHNSON UNIVERSITY HOSPITAL   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

BCL 2; Ki 67; Microglandular adenocarcinoma; Microglandular hyperplasia; Mucinous endometrial adenocarcinoma; p16; Survivin; Vimentin

Indexed keywords

CD34 ANTIGEN; COMMON ACUTE LYMPHOBLASTIC LEUKEMIA ANTIGEN; KI 67 ANTIGEN; PROTEIN BCL 2; PROTEIN P16; SURVIVIN; VIMENTIN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CURETTAGE; DIFFERENTIAL DIAGNOSIS; ENDOMETRIUM BIOPSY; ENDOMETRIUM CARCINOMA; ENDOMETRIUM TUMOR; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MUCINOUS CARCINOMA; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; STROMA CELL; UTERINE CERVIX CARCINOMA; UTERINE CERVIX EPITHELIUM; UTERINE CERVIX HYPERPLASIA; UTERINE ENDOCERVIX; COLLOID CARCINOMA; COMPARATIVE STUDY; ENDOMETRIUM HYPERPLASIA; MIDDLE AGED; PATHOLOGY; RETROSPECTIVE STUDY;

ADENOCARCINOMA, MUCINOUS; AGED; AGED, 80 AND OVER; DIAGNOSIS, DIFFERENTIAL; ENDOMETRIAL HYPERPLASIA; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY;

EID: 58149192483     PISSN: 02771691     EISSN: None     Source Type: Journal    
DOI: 10.1097/PGP.0b013e318177eadc     Document Type: Article

References (27)

1. Ross JC, Eifel PJ, Cox RS, et al. Primary mucinous adenocarcinoma of the endometrium. A clinicopathologic and histochemical study. Am J Surg Pathol. 1983;7:715-29.
2. Tavassoli FA, Devilee P, eds. WHO Classification of Tumours: Tumours of the Breast and Female Genital Organs. Lyon, France: IARC Press; 2003:224.
3. Kurman R, ed. Blaustein's Pathology of the Female Genital Tract. 5th ed. New York, NY: Springer-Verlag; 2002:527.
4. Young RH, Scully RE. Uterine carcinomas simulating microglandular hyperplasia. A report of six cases. Am J Surg Pathol. 1992;16:1092-7.
5. Zaloudek Ch, Hayashi GM, Ryan IP, et al. Microglandular adenocarcinoma of the endometrium: a form of mucinous adenocarcinoma that may be confused with microglandular hyperplasia of the cervix. Int J Gynecol Pathol. 1997;16:52-9.
6. Fukunaga M. Mucinous endometrial adenocarcinoma simulating microglandular hyperplasia of the cervix. Pathol Int. 2000;50:541-5.
7. McCluggage WG, Perenyei M. Microglandular adenocarcinoma of the endometrium. Histopathology. 2000;37:285-7.
8. Zamecnik M, Skalova A, Opatrny V. Microglandular adenocarcinoma of the uterus mimicking microglandular cervical hyperplasia. Ann Diagn Pathol. 2003;7:180-6.
9. Karateke A, Haliloglu B, Atay V, et al. A case of microglandular adenocarcinoma of the endometrium. Gynecol Oncol. 2005;99:778-81.
10. Da Forno PD, McGregor AH, Brown LJ. Microglandular hyperplasia: a pitfall in the diagnosis of microglandular type endometrioid adenocarcinoma. Histopathology. 2005;46:346-8.
11. Giordano G, D'Adda T, Gnetti L, et al. Endometrial mucinous microglandular adenocarcinoma: morphologic, immunohistochemical features, and emphasis in the human papillomavirus status. Int J Gynecol Pathol. 2006;25:77-82.
12. Melhem MF, Tobon H. Mucinous adenocarcinoma of the endometrium: a clinico-pathological review of 18 cases. Int J Gynecol Pathol. 1987;6:347-55.
13. Greeley C, Schroeder S, Silverberg SG. Microglandular hyperplasia of the cervix: a true "pill" lesion? Int J Gynecol Pathol. 1995;14:50-4.
14. Qiu W, Mittal K. Comparison of morphologic and immunohistochemical features of cervical microglandular hyperplasia with low-grade mucinous adenocarcinoma of the endometrium. Int J Gynecol Pathol. 2003;22:261-5.
15. Alkushi A, Irving J, Hsu F, et al. Immunoprofile of cervical and endometrial adenocarcinomas using a tissue microarray. Virchows Arch. 2000;442:271-7.
16. McCluggage WG, Sumathi VP, McBride HA, et al. A panel of immunohistochemical stains, including carcinoembryonic antigen, vimentin, and estrogen receptor, aids the distinction between primary endometrial and endocervical adenocarcinomas. Int J Gynecol Pathol. 2001;21:11-5.
17. Castrillon DH, Lee KR, Nucci MR. Distinction between endometrial and endocervical adenocarcinoma: an immunohistochemical study. Int J Gynecol Pathol. 2001;21:4-10.
18. Kamoi S, Al Juboury M, Akin MR, et al. Immunohistochemical staining in the distinction between primary endometrial and endocervical adenocarcinomas: another viewpoint. Int J Gynecol Pathol. 2002;21:217-23.
19. Pirog EC, Isacson C, Szabolcs MJ, et al. Proliferative activity of benign and neoplastic endocervical epithelium and correlation with HPV DNA detection. Int J Gynecol Pathol. 2002;21:22-6.
20. Murphy N, Heffron CC, King B, et al. p16INK4A positivity in benign, premalignant and malignant cervical glandular lesions: a potential diagnostic problem. Virchows Arch. 2004;445:610-5.
21. Pallares J, Martinez-Guitarte JL, Dolcet X, et al. Survivin expression in endometrial carcinoma: a tissue microarray study with correlation with PTEN and STAT-3. Int J Gynecol Pathol. 2005;24:247-53.
22. Frost M, Jarboe EA, Orlicky D, et al. Immunohistochemical localization of survivin in benign cervical mucosa, cervical dysplasia, and invasive squamous cell carcinoma. Am J Clin Pathol. 2002;177:738-44.
23. McCluggage WG, Maxwell P. Bcl-2 and p21 staining of cervical tuboendometrial metaplasia. Histopathology. 2002;40:107-8.
24. Barroeta JE, Pasha TL, Acs G, et al. Immunoprofile of endocervical and endometrial stromal cells and its potential application in localization of tumor involvement. Int J Gynecol Pathol. 2007;26:76-82.
25. Nielsen GP, Stemmer-Rachamimov AO, Shaw J, et al. Immunohistochemical survey of p16INK4A expression in normal human adult and infant tissues. Lab Invest. 1999;79:1137-43.
26. Shiozawa T, Nikaido T, Shimizu M, et al. Immunohistochemical analysis of the expression of cdk4 and p16INK4 in human endometrioid-type endometrial carcinoma. Cancer. 1997;80:2250-6.
27. McCluggage WG, Jenkins D. p16 immunoreactivity may assist in the distinction between endometrial and endocervical adenocarcinoma. Int J Gynecol Pathol. 2003;22:231-5.